press release

January 11, 2026

− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) – − Company Provides 2026 Combined Net Product Revenue Guidance of $4,900 Million to $5,300 Million, Driven Primarily by Total TTR Net Product Revenue Guidance of $4,400 Million to $4,700 Million – – ...

press release

December 3, 2025

– Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director – CAMBRIDGE, Mass. (BUSINESS WIRE) Dec. 3, 2025 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and ...

press release

October 30, 2025

− Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) – − Continued Broad Access and Balanced Utilization of AMVUTTRA Across All ATTR CM Patient Segments – − Presented New Data from the HELIOS B Phase 3 Study at ...

news

October 24, 2025

“Closing gaps in care for people with transthyretin mediated (ATTR) amyloidosis starts with listening to patients and families about what truly matters in their care journey.” These words shared by Christine Chiti, clinical TTR nurse specialist at the Royal Free Hospital, UK, during the International ATTR 2025 Meeting for Patients and Doctors in Baveno, Italy capture the spirit behind World ...

Web Page

October 1, 2025

Our Company MAKING OUR MEDICINE Technical Operations and Manufacturing at Alnylam Precise chemistry, innovative delivery methods, advanced analytics, and cutting edge manufacturing allow Alnylam to pioneer the RNAi revolution™ and advance scientific discoveries into the clinic with industry leading speed and success rates. Our platform approach and operational agility ultimately results in new RNA based medicines for more patients, sooner. Alnylam’s ...

press release

October 1, 2025

- Global Cardiovascular Outcomes Trial will Enroll ~11,000 Patients Across 35 Countries to Evaluate Zilebesiran as a Novel Biannual Treatment Trial to Assess Zilebesiran in Patients with Uncontrolled Hypertension with Either Established or at High Risk of Cardiovascular Disease Milestone Payment of $300 Million Triggered Under Global Collaboration and License Agreement with Partner Roche CAMBRIDGE, Mass. (BUSINESS WIRE) Oct. 1, 2025 ...

news

September 9, 2025

At Alnylam, we think of ourselves as being "fiercely innovative" (which is also one of our core values) because we believe that we have the ability to drive new discoveries from concept to cure in a way that transforms the treatment of disease. For over 20 years, we’ve nurtured a culture that fosters creativity and collaboration to empower innovation across the entire company—from ...

press release

August 30, 2025

- Phase 3 Trial Informed by KARDIA 3 Phase 2 Study Results Presented as a Late Breaking Abstract at the European Society of Cardiology Congress 2025 Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 Zilebesiran Displayed Encouraging Safety When ...

press release

August 11, 2025

- Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST) CAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 11, 2025 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress ...

press release

July 31, 2025

− Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR CM in ...